Stockscreener 앱 받기
1.59
0.63%
-0.01
전일 마감가:
$1.60
열려 있는:
$1.585
하루 거래량:
27,342
Relative Volume:
0.27
시가총액:
$67.37M
수익:
$6.21M
순이익/손실:
$-19.92M
주가수익비율:
-1.5143
EPS:
-1.05
순현금흐름:
$-16.76M
1주 성능:
-7.56%
1개월 성능:
-18.04%
6개월 성능:
-32.05%
1년 성능:
-40.67%
1일 변동 폭
$1.58
$1.65
1주일 범위
$1.51
$1.80
52주 변동 폭
$1.51
$3.798
InspireMD Inc. Stock (NSPR) Company Profile
명칭
InspireMD Inc.
전화
972 3 6917691
주소
4 Menorat Hamaor Street, Tel Aviv
NSPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
1.59 | 67.79M | 6.21M | -19.92M | -16.76M | -1.05 |
|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2016-01-07 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2013-11-26 | 개시 | Oppenheimer | Outperform |
InspireMD Inc. 주식(NSPR)의 최신 뉴스
Performance Recap: Is M tron Industries Inc stock a good dividend stockDividend Hike & Fast Gain Stock Trading Tips - baoquankhu1.vn
Wall Street Recap: Can InspireMD Inc keep up with sector leadersVolume Spike & Consistent Return Strategy Ideas - baoquankhu1.vn
Buyback Watch: Is InspireMD Inc stock risky to hold nowQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Options Flow: Can InspireMD Inc be recession proofJuly 2025 Intraday Action & Fast Moving Stock Watchlists - baoquankhu1.vn
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC) - The Manila Times
InspireMD's CGuard® Prime Carotid Stent System Achieves Landmark Safety and Efficacy Results in C-GUARDIANS Trial Published in JACC - Quiver Quantitative
New carotid stent study reports low stroke rates for high-risk patients - Stock Titan
Chipmakers Recap: Can InspireMD Inc outperform in the next rally2025 Growth vs Value & Daily Chart Pattern Signals - baoquankhu1.vn
Published on: 2026-01-10 23:14:00 - Улправда
InspireMD (NASDAQ:NSPR) shareholders have endured a 81% loss from investing in the stock five years ago - Yahoo Finance
Will InspireMD Inc. (II2) stock outperform value peersProfit Target & Expert Approved Momentum Trade Ideas - Улправда
Why InspireMD Inc. stock could be next big winnerPortfolio Performance Report & Growth Focused Stock Reports - ulpravda.ru
Will InspireMD Inc. stock continue dividend increasesMarket Growth Report & Advanced Technical Signal Analysis - Улправда
Will InspireMD Inc. (II2) stock benefit from sector leadership2025 Macro Impact & Weekly Return Optimization Alerts - Улправда
How InspireMD Inc. stock compares to growth peersTrade Exit Summary & Daily Entry Point Trade Alerts - Улправда
InspireMD (NYSE:NSPR) Trading Down 6.2%Should You Sell? - MarketBeat
InspireMD (NYSE:NSPR) Trading Down 6.2% – Should You Sell? - Defense World
InspireMD (NSPR) price target decreased by 11.11% to 4.08 - MSN
Head to Head Analysis: InspireMD (NYSE:NSPR) versus Minerva Surgical (NASDAQ:UTRS) - Defense World
Is InspireMD (NASDAQ:NSPR) In A Good Position To Invest In Growth? - Sahm
Will InspireMD Inc. stock gain from lower inflationWeekly Trade Analysis & Low Risk Entry Point Guides - Улправда
Working capital per share of InspireMD Inc. – DUS:II2 - TradingView — Track All Markets
Can InspireMD Inc. stock hit record highs again2025 Breakouts & Breakdowns & Stepwise Swing Trade Plans - Улправда
Aug Update: Will InspireMD Inc. (II2) stock outperform value peersJuly 2025 Catalysts & Safe Capital Preservation Plans - Улправда
Why InspireMD Inc. stock is considered a top pickJuly 2025 Highlights & Weekly High Return Forecasts - Улправда
Will InspireMD Inc. (II2) stock profit from fiscal stimulusBreakout Watch & Verified Momentum Watchlists - Улправда
InspireMD’s new study on neuroprotection system: A potential game-changer? - MSN
Is InspireMD Inc a good long term investmentREITs Market Trends & Capital Efficiency Improvement - earlytimes.in
InspireMD’s Pivotal Study on CGuard Prime Stent System: A Potential Game-Changer - MSN
InspireMD’s New Study on Neuroprotection System: A Potential Game-Changer? - TipRanks
Aug Selloffs: How InspireMD Inc stock compares to growth peers2025 Institutional Moves & Daily Growth Stock Tips - moha.gov.vn
Head-To-Head Review: Biotricity (NASDAQ:BTCY) versus InspireMD (NYSE:NSPR) - Defense World
Peter A. Soukas Joins InspireMD as Chief Medical Officer - Medical Product Outsourcing
Investment Report: Will InspireMD Inc stock gain from lower inflationWeekly Stock Analysis & Reliable Price Breakout Signals - moha.gov.vn
Total debt per share of InspireMD Inc. – MUN:II2 - TradingView
InspireMD Director Paul Stuka Acquires 10,130 Shares - TradingView
Dir Stuka Buys 10,130 ($18.7K) Of InspireMD Inc [NSPR] - TradingView — Track All Markets
Can InspireMD Inc. (II2) stock survive global slowdownM&A Rumor & High Conviction Trade Alerts - Newser
Is InspireMD Inc. (II2) stock supported by strong fundamentalsWeekly Gains Summary & Weekly Sector Rotation Insights - Newser
InspireMD (NSPR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Financial Contrast: InspireMD (NYSE:NSPR) vs. Biostage (OTCMKTS:BSTG) - Defense World
How InspireMD Inc. stock performs in rate cut cyclesTreasury Yields & Verified Swing Trading Watchlists - BỘ NỘI VỤ
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results - ADVFN
InspireMD (NYSE:NSPR) Shares Up 2%Should You Buy? - MarketBeat
InspireMD announces publication of CREST-2 data in NEJM - MSN
Lake Street Reaffirms Their Buy Rating on InspireMD (NSPR) - The Globe and Mail
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
InspireMD Celebrates Positive Outcomes from CREST-2 Study Supporting Carotid Stenting for Asymptomatic Patients - Quiver Quantitative
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting - The Manila Times
Landmark CREST-2 Study Published in the New England Journal - GlobeNewswire
InspireMD announces inducement grants - Medical Buyer
InspireMD Inc. (NSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
1.96%
자본화:
|
볼륨(24시간):